Recent studies found that polymorphism of PACSIN2 is associated with drug‐induced hematotoxicity in patients with ALL undergoing therapy,24, 39 showing the potential effects of PACSIN2 on hematopoiesis suppression. Here, PACSIN2 is linked to acute lymphoblastic leukemia.